Department of Second Neurology, Handan First Hospital, Handan, Hebei, China.
Clin Neuropharmacol. 2020 Jul/Aug;43(4):93-99. doi: 10.1097/WNF.0000000000000394.
The objective of this study was to investigate the efficacy and safety of Ginkgo biloba preparation for the treatment of Alzheimer disease (AD).
Both English (PubMed, Embase, Cochrane Library databases, and the Cochrane Controlled Trials Register) and Chinese (WanFang, Chinese Biomedical, CNKI, and VIP databases) databases were systematically and independently searched by 2 authors from their inception until July 3, 2019. All relevant studies included AD patients who were treated with Ginkgo biloba. The efficacy and safety of the medicine were used as the main measurement index.
Seven studies (N = 939) were identified and analyzed. When compared with placebo, Ginkgo biloba showed exact validity in cognitive function and global clinical assessment (cognitive function section: risk ratio = 1.98, 95% confidence interval = 1.52-2.59, Z = 5.12, P < 0.001; according to Clinical Global Impression Change: odds ratio = 3.119, 95% confidence interval = 2.206-4.410, Z = 6.44, P < 0.001). Adverse events were mild.
Ginkgo biloba preparation has reliable efficacy of cognitive function and global clinical assessment and safety in the treatment of AD.
本研究旨在探讨银杏叶制剂治疗阿尔茨海默病（AD）的疗效和安全性。
由 2 位作者分别从建库起至 2019 年 7 月 3 日，通过英文（PubMed、Embase、Cochrane 图书馆数据库和 Cochrane 对照试验登记库）和中文（万方、中国生物医学、CNKI 和 VIP 数据库）数据库系统、独立地检索所有相关研究。所有纳入的研究均为 AD 患者使用银杏叶制剂治疗的研究。药物的疗效和安全性作为主要测量指标。
共确定并分析了 7 项研究（N = 939）。与安慰剂相比，银杏叶在认知功能和整体临床评估方面具有确切的疗效（认知功能部分：风险比=1.98，95%置信区间=1.52-2.59，Z = 5.12，P < 0.001；根据临床总体印象变化：比值比=3.119，95%置信区间=2.206-4.410，Z = 6.44，P < 0.001）。不良事件轻微。
银杏叶制剂治疗 AD 具有可靠的认知功能和整体临床评估疗效和安全性。
